Stoke Therapeutics
Develops antisense medicines that restore protein expression in severe genetic diseases.
Something off on this page? Send us feedback.
Profile
Develops TANGO antisense medicines that increase protein expression from working gene copies, led by pivotal-stage zorevunersen for Dravet syndrome and early-stage STK-002 for inherited optic atrophy. Has no approved products; revenue comes from Biogen and Acadia collaborations.
Develops antisense oligonucleotide medicines that use the TANGO platform to redirect RNA splicing and increase protein expression from a working gene copy. Zorevunersen, for SCN1A-related Dravet syndrome, has a fully enrolled primary analysis cohort in the global pivotal EMPEROR study. STK-002 is dose escalating in a first-in-human study for OPA1-linked autosomal dominant optic atrophy, while a partnered SYNGAP1 program and earlier central-nervous-system research extend the pipeline.
Leads zorevunersen's global development and retains commercial rights in the United States, Canada, and Mexico; Biogen holds rights elsewhere and shares development costs. Collaboration and licensing agreements with Biogen and Acadia generate current revenue. The same splice-switching design underpins its clinical programs across haploinsufficiency disorders. No products are approved, and operations depend on trial outcomes, regulatory clearance, collaborators, and third-party manufacturers.
Company facts
Key statistics
Year to date +2.3% · Average volume (30d) 828.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 4, 2026 | Canaccord Genuity | Reiterate | Buy | $36 | $58 |
| Jul 13, 2026 | Goldman Sachs | Initiate | Buy | $44 | |
| Feb 23, 2026 | Wolfe Research | Target | $40 | ||
| Feb 5, 2026 | Guggenheim | Target | $60 | ||
| Jan 12, 2026 | Wedbush | Reiterate | Outperform | $36 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | −$0.80 | −$0.93 | −17.0% | $4.9M | $9.3M | +90.7% | +7.14% |
| May 7, 2026Q1 FY26 | −$0.80 | −$0.79 | +1.3% | $6.5M | $6.2M | −3.9% | +0.30% |
| Mar 16, 2026Q4 FY25 | −$0.75 | −$0.97 | −29.3% | $5.8M | $1.4M | −76.0% | −3.21% |
| Nov 4, 2025Q3 FY25 | −$0.54 | −$0.65 | −20.4% | $4.6M | $10.6M | +133.4% | −9.94% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $158.6M | $13.8M | $10.6M | $1.4M | $6.2M | $9.3M | |
| Gross profit | $158.6M | $13.8M | $9.6M | $347.0K | $5.2M | $8.2M | |
| Operating income | $111.2M | −$27.3M | −$43.1M | −$61.4M | −$53.4M | −$65.4M | |
| Net income | $112.9M | −$23.5M | −$38.3M | −$57.9M | −$50.0M | −$61.6M | |
| Diluted EPS | $1.90 | −$0.40 | −$0.65 | −$0.99 | −$0.79 | −$0.93 | |
| Gross margin | 100.0% | 100.0% | 90.7% | 24.8% | 83.2% | 87.8% | |
| Operating margin | 70.2% | -197.6% | -405.3% | -4,382.2% | -857.6% | -701.7% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $12.4M · FY23 $8.8M · FY24 $36.6M · FY25 $184.4M
Revenue by product · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $292.8M · Total debt $2.7M · Total assets $394.0M · Shareholders' equity $345.5M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 64.53M · Float 48.45M · 75.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.88M | 9.11% | 13F | Aug 7, 2026 |
| RTW Investments, LP | 5.62M | 8.72% | 13F | Aug 14, 2026 |
| FMR LLC | 5.31M | 8.23% | 13F | Aug 13, 2026 |
| LYNX1 Capital Management LP | 4.04M | 6.26% | 13F | Aug 13, 2026 |
| Redmile Group, LLC | 3.95M | 6.12% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Edward M. MD Kaye | director | −12,567 | $32.03 |
| Aug 18, 2026 | Barry Ticho | officer: CHIEF MEDICAL OFFICER | −4,767 | $32.03 |
| Aug 18, 2026 | Jonathan Allan | officer: GENERAL COUNSEL & CORP SEC | −2,861 | $32.03 |
| Aug 3, 2026 | Barry Ticho | officer: CHIEF MEDICAL OFFICER | −7,176 | $29.04 |
| Jul 1, 2026 | Barry Ticho | officer: CHIEF MEDICAL OFFICER | −7,228 | $32.66 |
Peers
- Jazz Pharmaceuticals
Owns Epidiolex, the leading approved Dravet anti-seizure blockbuster
- Harmony Biosciences
Phase 3 oral 5-HT2 agonist EPX-100 targets the same Dravet population
- Ionis Pharmaceuticals
ASO pioneer with direct SCN1A Dravet program (ION337) mirroring zorevunersen
- Bright Minds Biosciences
Phase 2 oral 5-HT2C agonist BMB-101 spans DEE incl. Dravet; Phase 3 planned
- Xenon Pharmaceuticals
Pre-clinical oral NaV1.1 potentiator XPC-837 targets the same SCN1A biology
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics | $31.62 | +0.03% | $2.04B | — | — | 74.0 | −32.5% |
| Jazz Pharmaceuticals | $244.54 | +0.02% | $15.36B | 16.7 | 9.7 | 3.3 | +15.6% |
| Harmony Biosciences | $39.21 | −0.03% | $2.27B | 12.7 | 10.1 | 2.4 | +30.3% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Bright Minds Biosciences | $72.81 | −0.15% | $712.6M | — | — | — | — |
| Xenon Pharmaceuticals | $59.99 | 0.00% | $5.80B | — | — | — | — |
| Median | 14.7 | 9.9 | 3.3 | +15.6% |